Skip to primary content

Biotech 365

Main menu

  • Biotech 365
  • Preclinical Studies Database
  • Healthcare Investors
  • Healthcare Companies

Post navigation

← Previous Next →

Gentronix – genotoxicity assays

Posted on by

Gentronix is biotech innovation and service company specialized in early screening, mechanistic follow-up and regulatory genotoxicity assays.

Gentronix – genotoxicity assays

Gentronix

Gentronix has developed world leading technology GreenScreen HC and BlueScreen HC to help researchers identify genotoxic hazard quickly and accurately whilst ensuring that safe compounds are not incorrectly labelled as toxic. Gentronix also provides a range of complementary assays and technology expertise that gives comprehensive access to the information needed to progress a project quickly and cost effectively. In addition to classical genotoxicity screening assays, Gentronix also offers  GreenScreen HC and BlueScreen HC which are accurate and fast in vitro human cell-based assays to assess the genotoxicity and cytotoxicity of compounds and mixtures. Thus Gentronix provides solutions to help researchers optimize drugs development. These novel, patented systems detect all known classes of genotoxin. Gentronix can also provides advices on follow-up strategies for mechanism elucidation to help scientists modify compounds to eliminate genotoxicity early in the process of drug discovery and development.

Gentronix is GLP compliant and provides a fully confidential service across its range of contract research activities and offers fast and efficient reporting that fits with the needs of any scientific organization. Gen-tronix proposes a 14 day turnaround as standard, or a “guaranteed 10 days” and “guaranteed 5 days” turnaround options for GreenScreen HC and BlueScreen HC. Gen-tronix also proposes 7-12 weeks for GLP studies and 2-3 weeks turnaround for other non-GLP assays. Gen-tronix is managed by John Nicholson (CEO), Richard Walmsley (CSO), Steve Beasley and John Yates.

More about Gentronix : www.gentronix.co.uk

Gentronix – early screening – mechanistic follow-up – regulatory genotoxicity assays – GreenScreen HC – BlueScreen HC – drug development – drug discovery

Gentronix- regulatory genotoxicity assay – Green Screen HC – Blue Screen HC – GreenScreenHC – BlueScreenHC – genotoxic hazard – genotoxic – genotoxicity – cytotoxicity – cytotoxic – John Nicholson – Richard Walmsley – Steve Beasley – John Yates

 

This entry was posted in Biotech Companies, Biotech Companies UK, Biotech Companies USA and tagged Blue Screen HC, BlueScreen HC, BlueScreenHC, cytotoxic, cytotoxicity, drug development, drug discovery, early screening, genotoxic, genotoxic hazard, genotoxicity, genotoxicity assays, Gentronix, Gentronix - genotoxicity assays, Green Screen HC, GreenScreen HC, GreenScreenHC, John Nicholson, John Yates, mechanistic follow-up, regulatory genotoxicity assay, regulatory genotoxicity assays, Richard Walmsley, Steve Beasley by . Bookmark the permalink.

Do you need to raise your next Funding round? In-Licensing / Out-Licensing of your assets? Distribution / Commercialization of your products? Want to create a spin-off with your IP?

Contact us!

Do you need a specific database in Healthcare (researchers, Biotech/Pharma companies, CRO/CDMO, etc.)?

Contact us!

Contact              Offers - Services - Licensing - Funding               Healthcare Venture Building               Biotech Jobs               Biotech & Pharma News
Proudly powered by WordPress